ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

brimonidine

Also written as “Brimonidine”, “Brimonidine Tartrate” and “CD07805/47 Gel”.

Its studies are mostly in Glaucoma · Rosacea · Glaucoma, Open-Angle · Conjunctivitis, Allergic · Hyperemia, led by 10 companies.

Drug pageBrimonidine: every studyMany companies study it; this page follows only the 52 they lead. All 104 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 6, 200752 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie220 open or runningphase 4since Apr 6, 2007Sep 12, 2005none ahead
Galderma Groupits history only100 open or runningphase 4since Sep 23, 2014Jun 12, 2008none ahead
Bausch Health Companiesits history only70 open or runningphase 3since Oct 8, 2013Oct 8, 2013none ahead
Eye Therapiesits history only30 open or runningphase 2since Jan 10, 2011Jan 10, 2011none ahead
Ocugenits history only30 open or runningphase 3since Jul 9, 2018Oct 10, 2017none ahead
Alconits history only20 open or runningphase 4since Dec 1, 2008May 28, 2003none ahead
Tarian Pharmaits history only22 open or runningphase 2since Jan 23, 2025Jan 23, 2025none ahead
Biogenits history only10 open or runningphase 4since Oct 1, 2015Oct 1, 2015none ahead
Innovative Medicalits history only10 open or runningphase 4since Jun 30, 2006Jun 30, 2006none ahead
Teva Pharmaceutical Industriesits history only10 open or runningphase 3since Oct 31, 2014Oct 31, 2014none ahead

Also a collaborator on its studies: ORA and Eurotrials Brasil Consultores Cientificos Ltda.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AbbVie only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 6 studies since Sep 12, 2005.

  1. Apr 1, 20082 phase 3 studies in GlaucomaNCT00652483, NCT00651612
  2. Apr 11, 2008Phase 2 study in Macular DegenerationNCT00658619 · 119 enrolled · United States, Australia, Germany and more
  3. Jun 5, 2008Phase 2 study in Glaucoma, Open-AngleNCT00693485 · 70 enrolled · United States, Israel
  4. Jan 13, 2009Phase 4 study in Glaucoma, Open-AngleNCT00822055 · 140 enrolled · Canada
  5. Sep 3, 2009Phase 2 study in Rhegmatogenous Macula-off Retinal DetachmentNCT00972374 · 44 enrolled · United States, India, Israel and more
  6. Jun 5, 2010Phase 4 study in Glaucoma, Angle-ClosureNCT01151904 · 17 enrolled · Thailand
  7. Oct 6, 20102 phase 3 studiesNCT01216943, NCT01217606
  8. Oct 20, 2010Phase 1 study in VitrectomyNCT01229410 · 24 enrolled · United States, Czech Republic
  9. Oct 26, 2010No phase study in GlaucomaNCT01229462 · 238 enrolled · China
  10. Nov 12, 2010Phase 3 study in Glaucoma, Open-AngleNCT01241240 · 192 enrolled · Colombia, Mexico
  11. Jan 31, 2012Phase 4 study in GlaucomaNCT01525173 · 137 enrolled · United States
  12. May 24, 2013Phase 2 study in GlaucomaNCT01863953 · 112 enrolled · United States
  13. Dec 2, 2013Phase 4 study in Glaucoma, Open-AngleNCT02003534 · 376 enrolled · China
  14. Mar 12, 2014Phase 2 study in Geographic AtrophyNCT02087085 · 310 enrolled · United States, Australia, France and more

TargetBeta

“Adrenergic receptor alpha-2 agonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
DexmedetomidinerulePfizerphase 446
OxymetazolineruleAbbViephase 420
Phentolamineruleopus-genetics-incphase 418
Epinephrinerulenasus-pharmaphase 417
tizanidineruleTeva Pharmaceutical Industriesphase 411
Clonidinerulepharmafinaphase 45
lofexidineruleuswm-llc-dba-us-worldmedsphase 315

Studies

All 22 AbbVie leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02087085Geographic Atrophy · United States, Australia, France and more2TerminatedMar 30, 2018310
NCT02003534Glaucoma, Open-Angle · China4CompletedFeb 2013376
NCT01863953Glaucoma · United States2CompletedDec 2013112
NCT01525173Glaucoma · United States4CompletedOct 2012137
NCT01241240Glaucoma, Open-Angle · Colombia, Mexico3CompletedSep 2013192
NCT01229462Glaucoma · China–CompletedSep 2011238
NCT01229410Vitrectomy · United States, Czech Republic1CompletedMay 201124
NCT01217606Glaucoma, Open-Angle · Brazil3CompletedSep 2014185
NCT01216943Glaucoma · India3CompletedAug 2012126
NCT01151904Glaucoma, Angle-Closure · Thailand4TerminatedFeb 201217
NCT00972374Rhegmatogenous Macula-off Retinal Detachment · United States, India, Israel and more2CompletedOct 201044
NCT00822055Glaucoma, Open-Angle · Canada4CompletedNov 2006140
NCT00693485Glaucoma, Open-Angle · United States, Israel2CompletedJan 201170
NCT00658619Macular Degeneration · United States, Australia, Germany and more2CompletedJun 1, 2010119
NCT00652483Glaucoma · United States3CompletedDec 2003433
NCT00651612Glaucoma · United States3CompletedJan 2007604
NCT00661479Retinitis Pigmentosa · United States, France, Germany and more2CompletedDec 200921
NCT00457795Glaucoma, Open-Angle · United States4CompletedFeb 200915
NCT00332436Ocular Hypertension · United States3CompletedNov 2001586
NCT00332384Ocular Hypertension · United States3CompletedNov 2001573
NCT00332345Ocular Hypertension · United States2CompletedAug 199973
NCT00168363Glaucoma3CompletedAug 2006207

How it is read

Names in the registry

  • “Brimonidine”, 4 entries
  • “Brimonidine Tartrate”, 4 entries
  • “CD07805/47 Gel”, 4 entries
  • “CD07805/47”, 3 entries
  • “400 µg Brimonidine Tartrate Implant”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.